Literature DB >> 6521992

Severe proliferative vitreoretinopathy and retinal detachment. II. Surgical results with scleral buckling.

A Yoshida, P C Ho, C L Schepens, J W McMeel, J E Duncan.   

Abstract

Prior to the era of vitrectomy, scleral buckling was used to treat 521 eyes with total retinal detachment and proliferative vitreoretinopathy (PVR) of various degrees of severity. The retina was reattached for at least six months in 46.9% of eyes; the anatomic success rate decreased with increasing severity of PVR. Within each grade of PVR, the reattachment rate was higher for eyes with smaller breaks than for eyes with larger breaks, and the prognosis was not worse when smaller breaks were found than when no breaks were found. The cumulative success rate rose with increasing number of reoperations. None of the anatomically successful cases had a final visual acuity of no light perception; 82.9% of them achieved a visual acuity of counting fingers or better. The prognosis for visual improvement after successful scleral buckling was unrelated to the preoperative severity of PVR. Severe intraoperative complications occurred in 5.0% of the eyes, all of which resulted in failure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6521992     DOI: 10.1016/s0161-6420(84)34096-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  3 in total

1.  Anatomic outcome of scleral buckling surgery in primary rhegmatogenous retinal detachment.

Authors:  F Afrashi; C Akkin; S Egrilmez; T Erakgun; J Mentes
Journal:  Int Ophthalmol       Date:  2006-09-07       Impact factor: 2.031

2.  The development of severe proliferative vitreoretinopathy after retinal detachment surgery. Grade B: a determining risk factor.

Authors:  M Bonnet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1988       Impact factor: 3.117

3.  Retinal detachment with proliferative vitreoretinopathy: surgical results with scleral buckling, closed vitrectomy, and intravitreous air injection.

Authors:  P C Ho; J W McMeel
Journal:  Br J Ophthalmol       Date:  1985-08       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.